Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today that Capricor CEO, Linda Marbán, Ph.D., will...

Click to view original post